Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Viromed Medical Expands ViroCAP Distribution to Six New Markets
TLDR
- Viromed Medical AG expands to six new markets, securing at least 3,000 additional device sales annually, boosting its competitive edge.
- Viromed Medical AG signed distribution agreements with six companies for ViroCAP in Spain, Portugal, Greece, Balkans, Romania, and Saudi Arabia, each with minimum purchase quantities.
- Viromed's cold plasma technology for skin conditions becomes more accessible across Europe and the Middle East, improving patient care.
- Viromed's ViroCAP uses cold atmospheric plasma, a novel technology, now entering diverse markets from Greece to Saudi Arabia.
Impact - Why it Matters
This expansion signifies a major step for Viromed Medical in establishing a global footprint for cold plasma technology. For healthcare providers in the new markets, it means access to an innovative, non-invasive treatment for skin conditions, potentially improving patient outcomes. For the company, it diversifies revenue streams and strengthens its position in the medical device industry, signaling growth and investment opportunities. For the broader healthcare ecosystem, it demonstrates the increasing acceptance and commercial viability of cold plasma therapy, which could lead to more widespread adoption and further innovation.
Summary
Viromed Medical AG, a German medical technology company specializing in cold plasma technology, has announced new distribution partnerships for its ViroCAP® device, expanding into six additional markets: Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia. The agreements, signed with six separate companies, each for an individual market, include minimum purchase quantities that are expected to yield additional sales of at least 3,000 devices per year. ViroCAP® is a mobile medical device that uses cold atmospheric plasma to treat skin conditions, targeting hospitals, private practice physicians, and surgical specialists.
CEO Uwe Perbandt highlighted the strategic importance of these partnerships, noting the strong interest from partners underscores the demand for the technology and marks a key step in the company's growth phase. Further partnerships for other countries are expected within four to six weeks. This expansion builds on Viromed's existing global network, which already includes exclusive distribution in ten Asian countries via Korean partner UMECO and a partnership with TriPart TITAN GmbH & Co. KG for Turkey.
Viromed Medical AG, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH, focusing on the distribution of cold plasma technology for medical use. The company has a broad customer base in the DACH region and aims to advance the adoption of cold plasma therapy globally. For more information, visit www.viromed-medical-ag.de or view the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Viromed Medical Expands ViroCAP Distribution to Six New Markets
